[The role of iron metabolism in myelodysplastic syndromes]

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Transfusion-dependent anemia in myelodysplastic syndromes (MDS) inevitably leads to iron overload.
• Iron overload is a significant negative prognostic factor in MDS patients.
• Serum ferritin and transfusion history are key diagnostic indicators for transfusional iron overload.

Purpose of the Study:

• To evaluate the efficacy and tolerability of deferasirox, an oral iron chelator, in MDS patients.
• To assess the impact of iron chelation therapy on peripheral cytopenias in MDS.
• To provide recommendations for initiating iron chelation therapy in MDS.

Main Methods:

• Review of studies investigating deferasirox in MDS patients.
• Analysis of data on iron overload diagnosis and management in MDS.
• Assessment of treatment guidelines for iron chelation in MDS.

Main Results:

• Deferasirox demonstrates efficacy and acceptable tolerability in MDS patients.
• A subset of 10-20% of MDS patients treated with deferasirox experienced improvement in peripheral cytopenia.
• Iron chelation therapy is advised after 20 red cell units in low-risk MDS and in select high-risk patients.

Conclusions:

• Iron chelation therapy is a crucial component of managing transfusion-dependent anemia in MDS.
• Deferasirox is an effective oral agent for treating iron overload in MDS.
• Timely initiation of iron chelation therapy can improve patient outcomes and potentially cytopenias.